Home › Immune System and Disorders › California
Immune System and Disorders clinical trials in California
19 studies for Immune System and Disorders are looking for participants at sites in California.
Cities in California
- Los Angeles9 studies
- Baldwin Park5 studies
- San Diego4 studies
- Mountain View3 studies
- San Francisco3 studies
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Kern Research, Inc., Bakersfield
- First OC Dermatology Research Inc, Fountain Valley
- Northridge Clinical Trials, Northridge
- and 2 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT07765888A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
- Kern Research, Inc., Bakersfield
- First OC Dermatology Research Inc, Fountain Valley
- Marvel Clinical Research, Huntington Beach
- and 4 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 6, 2026 · NCT07783425Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- PCR Oncology, Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- Washington Health, Fremont
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Nov 4, 2026 · NCT04242095A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06722235A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Chula Vista
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Oct 30, 2026 · NCT07541287A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06948318A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Stanford University, Dept. of Dermatology, Redwood City
- UC Davis, Dept. of Dermatology, Sacramento
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- City of Hope, Duarte
- Providence St. John's Health Center, Santa Monica
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT03328078A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- City of Hope, Duarte
- University of California, Irvine Medical Center - Hematology/Oncology, Orange
- Stanford University School of Medicine, Stanford
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- City of Hope, Duarte
- Stanford University, Palo Alto
- UCSF, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 1, Lancaster
- Inmagene Site 23, Los Angeles
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Aug 12, 2026 · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443Atacicept in Multiple Glomerular Diseases
- Vera Therapeutics, Brisbane
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 26, 2026 · NCT06983028A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- University of California, San Francisco, San Francisco
RecruitingPhase 2
All ages · All sexes · Updated Jun 2, 2026 · NCT05787574Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
- USC / Norris Comprehensive Cancer Center, Los Angeles
RecruitingObservational studyHealthy volunteers welcome
Ages 19 and older · All sexes · Updated Apr 2, 2026 · NCT03207854A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- City of Hope National Medical Center, Duarte
- Ronald Regan UCLA Medical Center, Los Angeles
- University of California Irvine Health, Orange
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 29, 2022 · NCT04684602From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.